Actelion Launches Increased Strength Formulation of Ventavis (Iloprost) for Pulmonary Arterial Hypertension in the Uni... (ry vasodilation and inhibits platelet ag...)

HOME >> BIOLOGY >> TECHNOLOGY

Actelion Launches Increased Strength Formulation of Ventavis (Iloprost) for Pulmonary Arterial Hypertension in the United States

Date:9/1/2009

ry vasodilation and inhibits platelet aggregation, among other benefits. Prostacyclin functions as a hormone, binding to receptors on smooth muscle cells, thereby affecting their function. Prostacyclin has multiple physiological effects, including vasodilation, inhibition of platelet aggregation, antiproliferation, anti-inflammation, and enhanced cardiac contractility.

In January 2007, Actelion announced the successful completion of its cash tender offer for shares of CoTherix, Inc., thereby strengthening its PAH franchise by adding Ventavis(R) to its product offerings in the United States. Bayer Schering Pharma - the inventor of Ventavis(R) - markets the drug as the first inhaled prostacyclin in Europe and other countries outside the US.

More information is available at www.4ventavis.com.

About Pulmonary Arterial Hypertension (PAH)

Pulmonary arterial hypertension (PAH) is a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs of an affected individual. The function of the heart and lungs is severely compromised, manifested by a limited exercise capacity, and, ultimately, a reduced life expectancy. Approximately 100,000 people in Europe and the United States are afflicted with either primary or secondary forms of the disease related to conditions or tissue disorders that affect the lungs, such as scleroderma, lupus, HIV/AIDS or congenital heart disease.

PAH is associated with structural changes in both the pulmonary vasculature and the right ventricle. Recent advances (1) in the understanding of the pathogenic factors leading to the pulmonary vascular disease have led to the development of new therapies targeting specific pathways (the prostacyclin pathway; the endothelin pathway; and the nitric oxide pathway) (2).
'/>"/>

0

GOOD

Page: 1 2 3
Related biology technology :

1. Actelion Announces Multiple Presentations on Tracleer(R) and the REVEAL Registry at CHEST 2007
2. Survey of More than 600 Patients Treated with Tracleer(R) (bosentan) Reveals Actelion Sure Steps(R) Patient Support Program Provides Valuable Educational Information
3. GeneraMedix, Inc. Announces Sale of Innovative Epoprostenol Formulation to Actelion Ltd.
4. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
5. Novozymes Launches Enzyme to Reduce Acrylamide in Food
6. Enova Medical Launches Exos Corporation
7. Elekta Launches New Linear Accelerator at 2007 ESTRO to Expand Cancer Treatment Availability
8. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
9. ThirdBiotech Networking Group Launches
10. BioReliance Launches Next-Generation Genotoxicity Screening Service
11. Midwest Research Institute Launches Center for Biological Safety and Security (CBS2)

Post Your Comments:

Actelion Launches Increased Strength Formulation of Ventavis (Iloprost) for Pulmonary Arterial Hypertension in the Uni...(ry vasodilation and inhibits platelet ag...)